1104, an Immune-resetting Peptide, for the Treatment of Allergic Disease
Time: 12:00 pm
day: Day One AM Non-Cell Based Approaches
Details:
- 1104 is a short linear peptide that binds to macrophages, and induces a tolerogenic response in allergic individuals and in preclinical models, long after the drug has been cleared from the serum
- In a human ex vivo study, matched PBMCs from allergics (n=16) and non-allergics (n=12) co-cultured with and without allergen and ‘1104 induced tolerogenic IL-10+ monocytes and Breg cells promoted induction of activated Treg cells, and reduced the proliferation of Th2 cells and Tfh cells
- Recent data in a P2a study, patients with moderate to severe EoE, showed that a short course of treatment with 1104, induces both Treg and Breg leading to a reduction in the numbers of oesophageal eosinophils, CD4 and CD8 cells and a significant decrease in clinical outcomes (DSQ)
